Capital loss incited Zuellig to aggressive business strategies.

Published: 2001-04-13 06:57:00

Updated: 2001-04-13 06:57:00

According to a financial report disclosed by a Zuellig's associated drug company, Zuellig Korea (President: Christian Stockling) made slow business progress last year to an extent that they encountered a whole capital lose and their associated drug makers who invested in business deals for sales,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK